• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双作用药物甲氨蝶呤在不同神经疾病、自身免疫性疾病和癌症中的概述。

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

机构信息

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

出版信息

Int J Mol Sci. 2020 May 14;21(10):3483. doi: 10.3390/ijms21103483.

DOI:10.3390/ijms21103483
PMID:32423175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7279024/
Abstract

Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases. In this paper, we take an overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy. In addition, the issue of the potential benefits of methotrexate in the development of neurological disorders in Alzheimer's disease or myasthenia gravis will be discussed.

摘要

甲氨蝶呤是叶酸的结构类似物,是治疗多种癌症或严重和耐药形式的自身免疫性疾病最有效和广泛使用的药物之一。在本文中,我们概述了关于甲氨蝶呤作用的复杂机制及其作为免疫抑制剂或化学治疗剂在肿瘤联合治疗中的应用的现有知识状态。此外,还将讨论甲氨蝶呤在阿尔茨海默病或重症肌无力的神经退行性疾病发展中的潜在益处的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7279024/fc48e9f078e8/ijms-21-03483-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7279024/562b4abf02b7/ijms-21-03483-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7279024/fc48e9f078e8/ijms-21-03483-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7279024/562b4abf02b7/ijms-21-03483-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7279024/fc48e9f078e8/ijms-21-03483-g002.jpg

相似文献

1
Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.双作用药物甲氨蝶呤在不同神经疾病、自身免疫性疾病和癌症中的概述。
Int J Mol Sci. 2020 May 14;21(10):3483. doi: 10.3390/ijms21103483.
2
Methotrexate: an old new drug in autoimmune disease.甲氨蝶呤:自身免疫性疾病中的一种古老新药。
Expert Rev Clin Immunol. 2014 Nov;10(11):1519-30. doi: 10.1586/1744666X.2014.962996. Epub 2014 Sep 22.
3
Immunosuppressive drugs in treatment of myasthenia gravis.免疫抑制药物治疗重症肌无力
Ann N Y Acad Sci. 1971 Sep 15;183:351-7. doi: 10.1111/j.1749-6632.1971.tb30764.x.
4
Immunointervention with cyclosporin A in autoimmune neurological disorders.用环孢素A对自身免疫性神经疾病进行免疫干预。
J Autoimmun. 1992 Apr;5 Suppl A:301-13. doi: 10.1016/0896-8411(92)90048-u.
5
Methotrexate for the neurologist.甲氨蝶呤治疗神经科疾病
Pract Neurol. 2024 Sep 13;24(5):369-375. doi: 10.1136/pn-2024-004156.
6
Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.双功能甲氨蝶呤在叶酸靶向纳米治疗递送中的机制及影响
Int J Mol Sci. 2015 Jan 13;16(1):1772-90. doi: 10.3390/ijms16011772.
7
Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.树枝状大分子的靶向药物递送:共价共轭药物与非共价药物包合物释放动力学的比较
Adv Drug Deliv Rev. 2005 Dec 14;57(15):2203-14. doi: 10.1016/j.addr.2005.09.014. Epub 2005 Nov 14.
8
Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation.接受叶酸补充的自身免疫性疾病患者中5,10-亚甲基四氢叶酸还原酶C677T基因多态性与甲氨蝶呤相关毒性的关系
Ann Rheum Dis. 2005 Dec;64(12):1791-2. doi: 10.1136/ard.2005.037218.
9
Methotrexate management of immune-mediated cochleovestibular disorders.甲氨蝶呤治疗免疫介导的耳蜗前庭疾病
Otolaryngol Head Neck Surg. 1997 Feb;116(2):146-52. doi: 10.1016/S0194-59989770316-4.
10
B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.B细胞在自身免疫性神经疾病病理生理学中的作用:一个可靠的治疗靶点。
Pharmacol Ther. 2006 Oct;112(1):57-70. doi: 10.1016/j.pharmthera.2006.03.005. Epub 2006 Apr 27.

引用本文的文献

1
Deciphering transcriptomic changes in chemobrain: a comprehensive review.解读化疗脑的转录组变化:全面综述
Acta Neuropathol Commun. 2025 Aug 30;13(1):186. doi: 10.1186/s40478-025-02102-z.
2
Management of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review.原发性中枢神经系统淋巴瘤合并射血分数降低的心力衰竭的管理:一项叙述性综述。
Cardiooncology. 2025 Aug 27;11(1):77. doi: 10.1186/s40959-025-00374-x.
3
Risk factors associated with high-dose methotrexate induced toxicities in primary central nervous system lymphoma.

本文引用的文献

1
Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.肿瘤坏死因子(TNF)阻断剂与类风湿关节炎和银屑病患者患阿尔茨海默病的风险降低相关。
PLoS One. 2020 Mar 23;15(3):e0229819. doi: 10.1371/journal.pone.0229819. eCollection 2020.
2
T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management.T 细胞亚群异常预示着炎症性关节炎疾病谱的进展:对治疗的启示。
Sci Rep. 2020 Feb 28;10(1):3669. doi: 10.1038/s41598-020-60314-w.
3
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
原发性中枢神经系统淋巴瘤中与高剂量甲氨蝶呤诱导毒性相关的危险因素。
Front Pharmacol. 2025 Aug 4;16:1561818. doi: 10.3389/fphar.2025.1561818. eCollection 2025.
4
Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies.无环萜类化合物的抗淋巴瘤活性及其构效关系:体内、体外和计算机模拟研究
Int J Mol Sci. 2025 Jun 13;26(12):5683. doi: 10.3390/ijms26125683.
5
Intralesional Immunotherapy for Non-Genital Viral Warts: A Review of Current Evidence and Future Perspectives.非生殖器病毒性疣的皮损内免疫疗法:当前证据与未来展望综述
Int J Mol Sci. 2025 Jun 12;26(12):5644. doi: 10.3390/ijms26125644.
6
Systemic Antifolate Chemotherapy Does Not Select for Fluconazole-Resistant : A Multicenter Clinical Study.全身抗叶酸化疗不会导致氟康唑耐药性的产生:一项多中心临床研究。
Pathogens. 2025 Jun 7;14(6):574. doi: 10.3390/pathogens14060574.
7
Where Do We Stand in the Management of Rheumatoid Arthritis Ahead of EULAR/ACR 2025?在2025年欧洲抗风湿病联盟/美国风湿病学会(EULAR/ACR)会议之前,我们在类风湿关节炎管理方面处于什么位置?
Clin Pract. 2025 May 28;15(6):103. doi: 10.3390/clinpract15060103.
8
Mechanisms of Total Glucosides of Paeony in Alleviating Methotrexate-Induced Liver Injury.芍药总苷减轻甲氨蝶呤所致肝损伤的机制
Drug Des Devel Ther. 2025 Apr 29;19:3407-3423. doi: 10.2147/DDDT.S521740. eCollection 2025.
9
Combating Methotrexate Resistance in Cancer Treatment: A Review on Navigating Pathways and Enhancing Its Efficacy With Fat-Soluble Vitamins.癌症治疗中对抗甲氨蝶呤耐药性:关于通过脂溶性维生素探寻途径并提高其疗效的综述
Scientifica (Cairo). 2025 Apr 16;2025:8259470. doi: 10.1155/sci5/8259470. eCollection 2025.
10
Effect of on dexamethasone-induced testicular toxicity in mice.[具体物质]对小鼠地塞米松诱导的睾丸毒性的影响。 (原文中“Effect of on”部分缺失具体物质,需补充完整才能准确翻译)
Avicenna J Phytomed. 2024 Sep-Oct;14(5):520-526. doi: 10.22038/AJP.2023.23584.
药物治疗类风湿关节炎的疗效:系统文献研究为 2019 年更新的 EULAR 类风湿关节炎管理建议提供信息。
Ann Rheum Dis. 2020 Jun;79(6):744-759. doi: 10.1136/annrheumdis-2019-216656. Epub 2020 Feb 7.
4
Maintenance immunosuppression in myasthenia gravis, an update.重症肌无力的维持性免疫抑制治疗:最新进展
J Neurol Sci. 2020 Mar 15;410:116648. doi: 10.1016/j.jns.2019.116648. Epub 2019 Dec 26.
5
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples.用于测定药物、生物和环境样品中甲氨蝶呤及其代谢物的分析方法。
J Pharm Anal. 2019 Dec;9(6):373-391. doi: 10.1016/j.jpha.2019.06.001. Epub 2019 Jun 20.
6
Safety of long-term intrathecal methotrexate in progressive forms of MS.长期鞘内注射甲氨蝶呤治疗进展型多发性硬化症的安全性。
Ther Adv Neurol Disord. 2019 Dec 3;12:1756286419892360. doi: 10.1177/1756286419892360. eCollection 2019.
7
High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature.大剂量静脉注射甲氨蝶呤治疗伴软脑膜疾病的乳腺癌:病例系列及文献综述
Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):189-193. doi: 10.1016/j.hemonc.2019.08.008. Epub 2019 Oct 14.
8
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.阿法替尼对比甲氨蝶呤用于铂类治疗后进展的复发性或转移性头颈部鳞状细胞癌亚洲患者的二线治疗(LUX-Head & Neck 3):一项开放标签、随机 III 期试验。
Ann Oncol. 2019 Nov 1;30(11):1831-1839. doi: 10.1093/annonc/mdz388.
9
Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery.载甲氨蝶呤聚合物纳米粒的制备及其体内外特性研究以改善淋巴递药
Int J Mol Sci. 2019 Jul 5;20(13):3312. doi: 10.3390/ijms20133312.
10
Lung cancer combined with methotrexate-associated lymphoproliferative disorder: A case report.肺癌合并甲氨蝶呤相关淋巴增殖性疾病:一例报告。
Int J Surg Case Rep. 2019;59:161-164. doi: 10.1016/j.ijscr.2019.05.033. Epub 2019 May 28.